Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The aim was to quantify tau protein and beta-amyloid (Abeta42) in the CSF of patients with sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), and controls. Double sandwich enzyme linked immunosorbent assays (ELISAs) were used for measurements. Tau was increased 58-fold in CJD and 3.5-fold in AD compared with controls, whereas Abeta42 was decreased 0.5-fold in both CJD and AD. A cut off level for tau protein at 2131 pg/ml successfully discriminated CJD from AD (100% specificity and 93% sensitivity). Tau protein concentration in CSF is probably an additional useful marker in differentiating CJD from AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · cited 1×
“Alzheimer's disease (AD) is the most common condition mimicking CJD, sharing some clinical and neuropathological features. Among several biomarkers, recently being evaluated for AD, the microtubule associated tau protein and the β-amyloid 1–42 (Aβ42), a constituent of senile plaques, are the most reliable. Increased C…”
Background
Cited by
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2243 · Cited by 413
Self-citationCSF tests in the differential diagnosis of Creutzfeldt-Jakob disease
Sanchez-Juan, P., Green, A., Ladogana, A., Cuadrado-Corrales, N., Sáanchez-Valle, R., Mitrováa, E., Stoeck, K., Sklaviadis, T., Kulczycki, J., Hess, K., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000230159.67128.00 · Cited by 293
Metadata
- Authors
- Kapaki, E.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2001-09-01
- Volume
- 71
- Issue
- 3
- Pages
- 401-403
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2107209192
- Cited by
- 133
- References
- 2
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? https://app.cochat.ai/papers/10.1136/jnnp.71.3.401
- The paper
- Kapaki, E. (2001). Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.71.3.401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.